SCHEMBL5459236

SCHEMBL5459236

COc1ccc(CN2CCN(c3cc(C)c(Br)cn3)CC2)cc1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
KDM4E B2RXH2 4/20 0.56
TSHR P16473 2/20 0.56
ALOX15 P16050 1/20 0.56
HTT P42858 3/20 0.53
LMNA P02545 2/20 0.53
MAPK1 P28482 2/20 0.53
KMT2A Q03164 1/20 0.52
PARP1 P09874 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.48
RAB9A P51151 2/20 0.48
DRD2 P14416 3/20 0.47
DRD4 P21917 2/20 0.47
DRD3 P35462 2/20 0.47
ACHE P22303 1/20 0.47
BACE1 P56817 1/20 0.47
STAT3 P40763 1/20 0.47
NPC1 O15118 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CRHBP P24387 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4711583 0.79 ALDH1A1 (0.51) ALDH1A1KDM4ETSHRALOX15HTT
SCHEMBL4712990 0.78 KDM4E (0.51) ALDH1A1KDM4ETSHRALOX15HTT
SCHEMBL29858194 0.78 KDM4E (0.51) ALDH1A1KDM4ETSHRALOX15HTT
SCHEMBL5904994 0.77 ALDH1A1 (0.56) ALDH1A1KDM4ETSHRALOX15HTT
SCHEMBL1600111 0.77 KMT2A (0.65) ALDH1A1KDM4ETSHRALOX15MAPK1
SCHEMBL13886164 0.76 CRHBP (0.73) ALDH1A1KDM4ETSHRALOX15MAPK1
SCHEMBL4708954 0.75 HTR7 (0.57) ALDH1A1KDM4ETSHRALOX15HTT
SCHEMBL9203924 0.75 KMT2A (0.56) ALDH1A1KDM4ETSHRHTTLMNA
SCHEMBL4711626 0.74 CRHBP (0.53) ALDH1A1KDM4ETSHRALOX15HTT
SCHEMBL18182316 0.72 MAPK1 (0.72) ALDH1A1KDM4ETSHRALOX15MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249616-A1 Substituted 1-Benzyl-4-Substituted Piperazine Analogues NEUROGEN CORPORATION (US) 2007-10-25 US disclosed
US-20070249616-A1 Substituted 1-Benzyl-4-Substituted Piperazine Analogues NEUROGEN CORPORATION (US) 2007-10-25 US disclosed
US-20070249616-A1 Substituted 1-Benzyl-4-Substituted Piperazine Analogues NEUROGEN CORPORATION (US) 2007-10-25 US disclosed
US-7253168-B2 Substituted 1-benzyl-4-substituted piperazine analogues NEUROGEN CORPORATION (US) 2007-08-07 US disclosed
US-7253168-B2 Substituted 1-benzyl-4-substituted piperazine analogues NEUROGEN CORPORATION (US) 2007-08-07 US disclosed
US-7253168-B2 Substituted 1-benzyl-4-substituted piperazine analogues NEUROGEN CORPORATION (US) 2007-08-07 US disclosed
US-20060142301-A1 Substituted 1-benzyl-4-substituted piperazine analogues NEUROGEN CORPORATION 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249616-A1 Substituted 1-Benzyl-4-Substituted Piperazine Analogues MCHR1, MCHR2, PRLHR ALDH1A1 793/4885KDM4E 1136/4885TSHR 199/4885
US-20060142301-A1 Substituted 1-benzyl-4-substituted piperazine analogues MCHR1, MCHR2, PRLHR ALDH1A1 793/4885KDM4E 1136/4885TSHR 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.